Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectMin Gao, Lawrence G. Hamann, Richard E. Nettles et al.|Nature|2010Cited by 940
The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus InfectionPaul M. Scola, Jialong Zhu, Ny Sin et al.|Journal of Medicinal Chemistry|2014Cited by 112
Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus InfectionPaul M. Scola, Fiona McPhee, Alan Xiangdong Wang et al.|Journal of Medicinal Chemistry|2014Cited by 69
<i>In Vivo</i> Patterns of Resistance to the HIV Attachment Inhibitor BMS-488043Nannan Zhou, Pin‐Fang Lin, Beata Nowicka-Sans et al.|Antimicrobial Agents and Chemotherapy|2010Cited by 54
A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infectionTarek Hassanein, David Gardiner, Karen Sims et al.|Journal of Hepatology|2015Cited by 53